跳转至内容
Merck
CN

855855

胞嘧啶β-D-呋喃阿拉伯糖苷 盐酸盐

98%

别名:

1-(β-D-呋喃阿拉伯糖苷)­胞嘧啶 盐酸盐, Ara-C 盐酸盐, 胞嘧啶阿拉伯糖苷 盐酸盐, 阿拉伯糖胞嘧啶 盐酸盐, 阿糖胞嘧啶 盐酸盐, 阿糖胞苷 盐酸盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C9H13N3O5 · HCl
化学文摘社编号:
分子量:
279.68
UNSPSC Code:
12352100
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


assay

98%

optical activity

[α]25/D +130°, c = 1 in H2O

mp

197-198 °C (lit.)

SMILES string

Cl[H].NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O

InChI

1S/C9H13N3O5.ClH/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8;/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16);1H/t4-,6-,7+,8-;/m1./s1

InChI key

KCURWTAZOZXKSJ-JBMRGDGGSA-N

Biochem/physiol Actions

Ara-C 被磷酸化为 Ara-CTP 并掺入 DNA。通过与拓扑异构酶 Ⅰ 形成剪切复合物来抑制 DNA 复制并导致 DNA 片段化,最终通过 PKC 信号通路诱导细胞凋亡。不抑制 RNA 合成。抗白血病药物。


法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Julie M Vose et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(13), 1662-1668 (2013-03-13)
This clinical trial evaluated standard-dose radioimmunotherapy with a chemotherapy-based transplantation regimen followed by autologous hematopoietic cell transplantation versus rituximab with the same regimen in patients with relapsed diffuse large B-cell lymphoma (DLBCL). Patients with chemotherapy-sensitive persistent or relapsed DLBCL were
Jorge Cortes et al.
The Lancet. Oncology, 14(4), 354-362 (2013-03-05)
Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elderly patients with relapsed or refractory acute myeloid leukaemia (AML). We aimed to compare two dosing regimens of tosedostat. In this randomised phase
Sergio Amadori et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(35), 4424-4430 (2013-10-16)
This randomized trial evaluated the efficacy and toxicity of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia (AML). Patients (n = 472) age 61 to 75 years were randomly assigned to induction